Peng Lin

Peng Lin

Auto-generated profile, based on publicly available information

Peng Lin

School of Life Sciences, Westlake University, 310024, Hangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
XRXiaojuan Ran
Xiaojuan Ran
JZJian Zheng
Jian Zheng
LCLingchao Chen
Lingchao Chen
ZXZhen Xia
Zhen Xia
YWYin Wang
Yin Wang
QXQi Xie
Qi Xie
Isocitrate dehydrogenase (IDH)–wild-type (WT) high-grade gliomas, especially glioblastomas, are highly aggressive and have an immunosuppressive tumor microenvironment. Although tumor-infiltrating immune cells are known to play a critical role in glioma genesis, their heterogeneity and intercellular interactions remain poorly understood. In this study, we constructed a single-cell transcriptome landscape of immune cells from tumor tissue and matching peripheral blood mononuclear cells (PBMC) from IDH-WT high-grade glioma patients. Our analysis identified two subsets of tumor-associated macrophages (TAM) in tumors with the highest protumorigenesis signatures, highlighting their potential role in glioma progression. We also investigated the T-cell trajectory and identified the aryl hydrocarbon receptor (AHR) as a regulator of T-cell dysfunction, providing a potential target for glioma immunotherapy. We further demonstrated that knockout of AHR decreased chimeric antigen receptor (CAR) T-cell exhaustion and improved CAR T-cell antitumor efficacy both in vitro and in vivo. Finally, we explored intercellular communication mediated by ligand–receptor interactions within the tumor microenvironment and PBMCs and revealed the unique cellular interactions present in the tumor microenvironment. Taken together, our study provides a comprehensive immune landscape of IDH-WT high-grade gliomas and offers potential drug targets for glioma immunotherapy.

8 November 2024 in The EMBO Journal
Verified
Journal Article
Open access
XWXianping Wang
Xianping Wang
YGYifan Guo
Yifan Guo
PLPeng Lin
Peng Lin
MYMin Yu
Min Yu
SSSha Song
Sha Song
XMXianjue Ma
Xianjue Ma
Hormone therapy resistance and the ensuing aggressive tumor progression present a significant clinical challenge. However, the mechanisms underlying the induction of tumor malignancy upon inhibition of steroid hormone signaling remain poorly understood. Here, we demonstrate that Drosophila malignant epithelial tumors show a similar reduction in ecdysone signaling, the main steroid hormone pathway. Our analysis of ecdysone-induced downstream targets reveals that overexpression of the nuclear receptor E75, particularly facilitates the malignant transformation of benign tumors. Genome-wide DNA binding profiles and biochemistry data reveal that E75 not only binds to the transcription factors of both Hippo and Notch pathways, but also exhibits widespread co-binding to their target genes, thus contributing to tumor malignancy. We further validated these findings by demonstrating that depletion of NR1D2 , the mammalian homolog of E75, inhibits the activation of Hippo and Notch target genes, impeding glioblastoma progression. Together, our study unveils a novel mechanism by which hormone inhibition promotes tumor malignancy, and describes an evolutionarily conserved role of the oncogene E75/NR1D2 in integration of Hippo and Notch pathway activity during tumor progression.

22 August 2025 in The EMBO Journal
Verified
Journal Article
Open access
SZSihua Zhao
Sihua Zhao
YGYifan Guo
Yifan Guo
XKXiaoyu Kuang
Xiaoyu Kuang
XLXiaoqin Li
Xiaoqin Li
CWChenxi Wu
Chenxi Wu
XMXianjue Ma
Xianjue Ma
Tumor heterogeneity, a hallmark of cancer, frequently leads to treatment failure and relapse. However, the intricate communication between various cell types within the tumor microenvironment and their roles in tumor progression in vivo remain poorly understood. Here we establish a novel tumor heterogeneity model in the Drosophila larval eye disc epithelium and dissect the in vivo mechanisms by combining sophisticated genetics with single-cell RNA sequencing. We found that mutation of the tricellular junction protein M6 in cells surrounding RasV12 benign tumors promotes their malignant transformation. Mechanistically, early RasV12//M6−/− tumors secrete Pvf1, which activates the Pvr receptor on hemocytes, facilitating their recruitment to the tumor site. These tumor-associated hemocytes secrete the Spätzle (Spz) ligand to activate the Toll receptor within the RasV12 tumors. This enhanced activation of the Toll pathway synergizes with RasV12 to promote malignant transformation through the JNK-Hippo signaling cascade. In summary, our study elucidates the complex interplay between genetically distinct oncogenic cells and between tumors and hemocytes, highlighting how hemocytes exploit the ancient innate immune system to coordinate tumor heterogeneity and drive tumor progression.